387 related articles for article (PubMed ID: 21768474)
21. Results of a phase 1-2 study of clofarabine in combination with cytarabine (ara-C) in relapsed and refractory acute leukemias.
Faderl S; Gandhi V; O'Brien S; Bonate P; Cortes J; Estey E; Beran M; Wierda W; Garcia-Manero G; Ferrajoli A; Estrov Z; Giles FJ; Du M; Kwari M; Keating M; Plunkett W; Kantarjian H
Blood; 2005 Feb; 105(3):940-7. PubMed ID: 15486072
[TBL] [Abstract][Full Text] [Related]
22. Phase I study of clofarabine in adult patients with acute myeloid leukemia in Japan.
Suzuki T; Yamauchi T; Ando K; Nagai T; Kakihana K; Miyata Y; Uchida T; Tabata Y; Ogura M
Jpn J Clin Oncol; 2013 Dec; 43(12):1177-83. PubMed ID: 24130086
[TBL] [Abstract][Full Text] [Related]
23. A randomized phase 2 study of idarubicin and cytarabine with clofarabine or fludarabine in patients with newly diagnosed acute myeloid leukemia.
Jabbour E; Short NJ; Ravandi F; Huang X; Xiao L; Garcia-Manero G; Plunkett W; Gandhi V; Sasaki K; Pemmaraju N; Daver NG; Borthakur G; Jain N; Konopleva M; Estrov Z; Kadia TM; Wierda WG; DiNardo CD; Brandt M; O'Brien SM; Cortes JE; Kantarjian H
Cancer; 2017 Nov; 123(22):4430-4439. PubMed ID: 28708931
[TBL] [Abstract][Full Text] [Related]
24. Remission re-induction chemotherapy with clofarabine, topotecan, thiotepa, and vinorelbine for patients with relapsed or refractory leukemia.
Steinherz PG; Shukla N; Kobos R; Steinherz L
Pediatr Blood Cancer; 2010 May; 54(5):687-93. PubMed ID: 20205253
[TBL] [Abstract][Full Text] [Related]
25. A pharmacodynamic study of sorafenib in patients with relapsed and refractory acute leukemias.
Pratz KW; Cho E; Levis MJ; Karp JE; Gore SD; McDevitt M; Stine A; Zhao M; Baker SD; Carducci MA; Wright JJ; Rudek MA; Smith BD
Leukemia; 2010 Aug; 24(8):1437-44. PubMed ID: 20535150
[TBL] [Abstract][Full Text] [Related]
26. A randomized study of clofarabine versus clofarabine plus low-dose cytarabine as front-line therapy for patients aged 60 years and older with acute myeloid leukemia and high-risk myelodysplastic syndrome.
Faderl S; Ravandi F; Huang X; Garcia-Manero G; Ferrajoli A; Estrov Z; Borthakur G; Verstovsek S; Thomas DA; Kwari M; Kantarjian HM
Blood; 2008 Sep; 112(5):1638-45. PubMed ID: 18565853
[TBL] [Abstract][Full Text] [Related]
27. Phase I/II trial of clofarabine and cytarabine in children with relapsed/refractory acute lymphoblastic leukemia (AAML0523): a report from the Children's Oncology Group.
Cooper TM; Razzouk BI; Gerbing R; Alonzo TA; Adlard K; Raetz E; Gamis AS; Perentesis J; Whitlock JA
Pediatr Blood Cancer; 2013 Jul; 60(7):1141-7. PubMed ID: 23335239
[TBL] [Abstract][Full Text] [Related]
28. Sorafenib treatment of FLT3-ITD(+) acute myeloid leukemia: favorable initial outcome and mechanisms of subsequent nonresponsiveness associated with the emergence of a D835 mutation.
Man CH; Fung TK; Ho C; Han HH; Chow HC; Ma AC; Choi WW; Lok S; Cheung AM; Eaves C; Kwong YL; Leung AY
Blood; 2012 May; 119(22):5133-43. PubMed ID: 22368270
[TBL] [Abstract][Full Text] [Related]
29. Preclinical and Pilot Study of Type I FLT3 Tyrosine Kinase Inhibitor, Crenolanib, with Sorafenib in Acute Myeloid Leukemia and FLT3-Internal Tandem Duplication.
Inaba H; van Oosterwijk JG; Panetta JC; Li L; Buelow DR; Blachly JS; Shurtleff S; Pui CH; Ribeiro RC; Rubnitz JE; Pounds S; Baker SD
Clin Cancer Res; 2022 Jun; 28(12):2536-2546. PubMed ID: 35344039
[TBL] [Abstract][Full Text] [Related]
30. Sorafenib Population Pharmacokinetics and Skin Toxicities in Children and Adolescents with Refractory/Relapsed Leukemia or Solid Tumor Malignancies.
Inaba H; Panetta JC; Pounds SB; Wang L; Li L; Navid F; Federico SM; Eisenmann ED; Vasilyeva A; Wang YD; Shurtleff S; Pui CH; Gruber TA; Ribeiro RC; Rubnitz JE; Baker SD
Clin Cancer Res; 2019 Dec; 25(24):7320-7330. PubMed ID: 31455680
[TBL] [Abstract][Full Text] [Related]
31. Compassionate use of sorafenib in FLT3-ITD-positive acute myeloid leukemia: sustained regression before and after allogeneic stem cell transplantation.
Metzelder S; Wang Y; Wollmer E; Wanzel M; Teichler S; Chaturvedi A; Eilers M; Enghofer E; Neubauer A; Burchert A
Blood; 2009 Jun; 113(26):6567-71. PubMed ID: 19389879
[TBL] [Abstract][Full Text] [Related]
32. Phase I dose-escalation trial of clofarabine followed by escalating doses of fractionated cyclophosphamide in children with relapsed or refractory acute leukemias.
Abd Elmoneim A; Gore L; Ricklis RM; Boklan J; Cooper T; Narendran A; Rolla K; Scott T; Arceci RJ
Pediatr Blood Cancer; 2012 Dec; 59(7):1252-8. PubMed ID: 22887831
[TBL] [Abstract][Full Text] [Related]
33. Final results of a phase 2 trial of clofarabine and low-dose cytarabine alternating with decitabine in older patients with newly diagnosed acute myeloid leukemia.
Kadia TM; Faderl S; Ravandi F; Jabbour E; Garcia-Manero G; Borthakur G; Ferrajoli A; Konopleva M; Burger J; Huang X; Wang X; Pierce S; Brandt M; Feliu J; Cortes J; Kantarjian H
Cancer; 2015 Jul; 121(14):2375-82. PubMed ID: 25809968
[TBL] [Abstract][Full Text] [Related]
34. Clofarabine and high-dose cytosine arabinoside in the treatment of refractory or relapsed acute myeloid leukaemia.
Tse E; Leung AY; Sim J; Lee HK; Liu HS; Yip SF; Kwong YL
Ann Hematol; 2011 Nov; 90(11):1277-81. PubMed ID: 21455604
[TBL] [Abstract][Full Text] [Related]
35. Phase I/II study of clofarabine, etoposide, and mitoxantrone in patients with refractory or relapsed acute leukemia.
Abbi KK; Rybka W; Ehmann WC; Claxton DF
Clin Lymphoma Myeloma Leuk; 2015 Jan; 15(1):41-6. PubMed ID: 25085441
[TBL] [Abstract][Full Text] [Related]
36. A phase I dose-escalation study of clofarabine in combination with fractionated gemtuzumab ozogamicin in patients with refractory or relapsed acute myeloid leukemia.
Foster MC; Amin C; Voorhees PM; van Deventer HW; Richards KL; Ivanova A; Whitman J; Chiu WM; Barr ND; Shea T
Leuk Lymphoma; 2012 Jul; 53(7):1331-7. PubMed ID: 22149206
[TBL] [Abstract][Full Text] [Related]
37. Hypertension and Life-Threatening Bleeding in Children with Relapsed Acute Myeloblastic Leukemia Treated with FLT3 Inhibitors.
Yılmaz Karapınar D; Karadaş N; Önder Siviş Z; Balkan C; Kavaklı K; Aydınok Y
Turk J Haematol; 2015 Sep; 32(3):263-6. PubMed ID: 25912283
[TBL] [Abstract][Full Text] [Related]
38. Clofarabine, cytarabine, and mitoxantrone in refractory/relapsed acute myeloid leukemia: High response rates and effective bridge to allogeneic hematopoietic stem cell transplantation.
Gill H; Yim R; Pang HH; Lee P; Chan TSY; Hwang YY; Leung GMK; Ip HW; Leung RYY; Yip SF; Kho B; Lee HKK; Mak V; Chan CC; Lau JSM; Lau CK; Lin SY; Wong RSM; Li W; Ma ESK; Li J; Panagiotou G; Sim JPY; Lie AKW; Kwong YL
Cancer Med; 2020 May; 9(10):3371-3382. PubMed ID: 32187883
[TBL] [Abstract][Full Text] [Related]
39. Flt3-ITD alters chemotherapy response in vitro and in vivo in a p53-dependent manner.
Pardee TS; Zuber J; Lowe SW
Exp Hematol; 2011 Apr; 39(4):473-485.e4. PubMed ID: 21288478
[TBL] [Abstract][Full Text] [Related]
40. Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia.
Zhang W; Konopleva M; Shi YX; McQueen T; Harris D; Ling X; Estrov Z; Quintás-Cardama A; Small D; Cortes J; Andreeff M
J Natl Cancer Inst; 2008 Feb; 100(3):184-98. PubMed ID: 18230792
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
